secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIxCrypto Holdings, Inc. (AIXC)
CIK:        0001460702
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001493152-24-014821
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Qualigen issues $1.1M convertible debenture & enters $1.5M co-development with Marizyme for DuraGraft
--------------------------------------------------------------------------------

- Issued $1.1M 8% convertible debenture and warrant to Yi Hua Chen upon exercise of Alpha option for $1M cash.
- Entered co-development agreement with Marizyme to fund commercial launch of FDA-cleared DuraGraft for CABG surgery.
- Qualigen to provide up to $1.5M funding; receives share of Marizyme's gross profit on US sales capped at 2x return.
- Exclusivity period until May 31, 2024 to negotiate broader strategic relationship with Marizyme.
- DuraGraft addresses >500,000 CABG procedures annually in US; Qualigen gains participation in revenue generation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460702/000149315224014821/0001493152-24-014821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460702/000149315224014821/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer